Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

21.2%

7 terminated/withdrawn out of 33 trials

Success Rate

63.2%

-23.4% vs industry average

Late-Stage Pipeline

36%

12 trials in Phase 3/4

Results Transparency

25%

3 of 12 completed trials have results

Key Signals

4 recruiting3 with results7 terminated

Enrollment Performance

Analytics

Phase 2

13(44.8%)

Phase 3

11(37.9%)

Phase 1

4(13.8%)

Phase 4

1(3.4%)

29Total

Phase 2(13)

Phase 3(11)

Phase 1(4)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (33)

Showing 20 of 33 trials

NCT06865417Phase 3Recruiting

A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis

Role: lead

NCT07553182Phase 3Recruiting

OLE Study With Filgotinib in JIA

Role: lead

NCT03025308Phase 3Completed

Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With Rheumatoid Arthritis

Role: lead

NCT06222034Phase 1Terminated

Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA)

Role: lead

NCT07554495Phase 3Recruiting

Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and Adolescents

Role: lead

NCT05323591Completed

Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France

Role: lead

NCT02914535Phase 3Active Not Recruiting

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

Role: lead

NCT06285539Phase 2Recruiting

Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases

Role: collaborator

NCT07363980Enrolling By Invitation

Coronary Computed Tomography Angiography In Rheumatoid Arthritis Study

Role: collaborator

NCT05817942Active Not Recruiting

Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)

Role: lead

NCT05785611Phase 3Active Not Recruiting

A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis

Role: lead

NCT04871919Active Not Recruiting

Prospective Observational Study of Filgotinib in Subjects With Rheumatoid Arthritis

Role: lead

NCT05724069Phase 2Completed

Velusetrag for the Treatment of Chronic Intestinal Pseudo-Obstruction (CIPO).

Role: lead

NCT01467726Phase 1Completed

Safety, Pharmacokinetics and Pharmacodynamics of Velusetrag in Healthy Elderly Subjects

Role: lead

NCT00391820Phase 2Completed

Evaluate the Safety and Efficacy of a 5-HT4 Agonist in Chronic Constipation (ACCORD Trial)

Role: lead

NCT03069131Phase 3Completed

Two Strategies of Primary Prophylaxis of Spontaneous Bacterial Peritonitis in Severe Cirrhotic Patients With Ascites

Role: collaborator

NCT05371925Phase 3Completed

Endothelial Protection in Post COVID-19 Patients With Sulodexide

Role: collaborator

NCT05150587Phase 2Completed

Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea

Role: lead

NCT05005052Phase 3Unknown

Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities

Role: collaborator

NCT03469050Phase 2Terminated

Rifaximin Delayed Release for the Prevention of Recurrent Acute Diverticulitis and Diverticular Complications.

Role: lead